These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35198504)

  • 41. What is the meaning of homocysteine in patients on dialysis?
    Silva de Almeida CC; Guerra DC; Vannucchi MT; Geleilete TJ; Vannucchi H; Chiarello PG
    J Ren Nutr; 2011 Sep; 21(5):394-400. PubMed ID: 21439851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relationship between homocysteine level and vitamins B12, B9 and B6 status in patients with chronic kidney disease.
    Shevchuk SV; Postovitenko KP; Iliuk IA; Bezsmertna HV; Bezsmertnyi YO; Kurylenko IV; Biloshytska AV; Baranova IV
    Wiad Lek; 2019; 72(4):532-538. PubMed ID: 31055527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The effect of baseline homocysteine level on the efficacy of enalapril maleate and folic acid tablet in lowering blood pressure and plasma homocysteine].
    Zhao F; Li JP; Wang SY; Guan DM; Ge JB; Hu J; Wang YN; Zhang FM; Huo Y
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2957-61. PubMed ID: 19080072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease.
    Elian KM; Hoffer LJ
    Metabolism; 2002 Jul; 51(7):881-6. PubMed ID: 12077735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A combination of omega-3 fatty acids, folic acid and B-group vitamins is superior at lowering homocysteine than omega-3 alone: A meta-analysis.
    Dawson SL; Bowe SJ; Crowe TC
    Nutr Res; 2016 Jun; 36(6):499-508. PubMed ID: 27188895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients.
    Essouma M; Noubiap JJ
    Biomark Res; 2015; 3():24. PubMed ID: 26346508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Homocysteine as a cardiovascular risk factor.
    Biasioli S; Schiavon R
    Blood Purif; 2000; 18(3):177-82. PubMed ID: 10859420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Homocysteine and cardiovascular disease: a review of the evidence.
    Wierzbicki AS
    Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homocysteine and C-reactive protein levels in haemodialysis patients.
    Koulouridis E; Tzilianos M; Katsarou A; Costimba I; Klonou E; Panagiotaki E; Georgalidis C; Krokida A; Delaportas N; Lachanas A; Karaliotas G; Kaliolia I
    Int Urol Nephrol; 2001; 33(2):207-15. PubMed ID: 12092633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Homocysteine and Hyperhomocysteinaemia.
    Zaric BL; Obradovic M; Bajic V; Haidara MA; Jovanovic M; Isenovic ER
    Curr Med Chem; 2019; 26(16):2948-2961. PubMed ID: 29532755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation].
    Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L
    Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
    Bostom AG; Carpenter MA; Kusek JW; Levey AS; Hunsicker L; Pfeffer MA; Selhub J; Jacques PF; Cole E; Gravens-Mueller L; House AA; Kew C; McKenney JL; Pacheco-Silva A; Pesavento T; Pirsch J; Smith S; Solomon S; Weir M
    Circulation; 2011 Apr; 123(16):1763-70. PubMed ID: 21482964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients.
    Herrmann W; Obeid R
    Clin Chem Lab Med; 2005; 43(10):1039-47. PubMed ID: 16197295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins.
    Haynes WG
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):391-9. PubMed ID: 12652108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperhomocysteinemia and atherosclerosis.
    Yang F; Tan HM; Wang H
    Sheng Li Xue Bao; 2005 Apr; 57(2):103-14. PubMed ID: 15830093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The kidney and homocysteine metabolism.
    Friedman AN; Bostom AG; Selhub J; Levey AS; Rosenberg IH
    J Am Soc Nephrol; 2001 Oct; 12(10):2181-2189. PubMed ID: 11562419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Homocysteine-lowering treatment in coronary heart disease.
    Cesari M; Rossi GP; Pessina AC
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Oct; 3(4):289-95. PubMed ID: 16250860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
    Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
    J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.